Gilbert Cisneros's ARQT trades
- The latest ARQT trade was a purchase on May 29, 2026, when ARQT closed at $21.46. It closed at $32.08 on Nov 3, 2026 (+49%).
Price changes use the closing price on each trade date, not the price actually paid, and ignore dividends. Filings report amounts only as ranges, so these figures show direction, not anyone's actual profit.
Gilbert Cisneros reported 3 ARQT transactions in 3 filings with the House Clerk for 2025–2026: 2 purchases and 1 sale of Arcutis Biotherapeutics, Inc. - Common stock, with trade dates from Dec 11, 2025 to May 29, 2026. The median gap between trade date and filing date is 32 days, and every trade was reported within 45 days.
- 3
- 2 / 1
- $3K – $45K
- 2026-06-08
ARQT transactions reported by Gilbert Cisneros
| Type | Owner | ||||
|---|---|---|---|---|---|
Arcutis Biotherapeutics, Inc. - Common stock ARQT | Purchase | Self | $1,001 - $15,000 | 2026-06-08 #20034713 | |
Arcutis Biotherapeutics, Inc. - Common stock ARQT | Purchase | Self | $1,001 - $15,000 | 2026-04-07 #20034285 | |
Arcutis Biotherapeutics, Inc. - Common stock ARQT | Sale | Self | $1,001 - $15,000 | 2026-01-12 #20033762 |
A row is a disclosure, not an execution record: the filing reports a date, a bracket, and the reported owner, but not the price, share count, or reason. Compare the trade date with the filing date to see how long the transaction stayed private.
How long disclosure took
Days from trade date to filing date for 3 rows. The STOCK Act allows 30 days from notification and no more than 45 days from the trade. A late row is a timing fact, not evidence of wrongdoing.
- 0–15 days
- 1
- 16–30 days
- 0
- 31–45 days
- 2
- Over 45 days
- 0
- Median / longest
- 32d / 35d
What Gilbert Cisneros's ARQT filings don’t tell you
A disclosure row records a trade date, an amount bracket, and who owned the asset. It does not say why the trade was made, whether the position is still held, or anything about the business behind the ticker: revenue trends, margins, balance-sheet risk, or valuation. Those answers are in company filings, not congressional ones.
To work through a company yourself, use our stock research checklist. Members get the full version of that work: one sourced investment call a month, with the numbers and the risks that would change the view.
Members-only research
What members are reading this month
- NVIDIA’s growth has a financing bill
Sales up about 18% on the prior quarter, receivables up about 55%, supply commitments at $279 billion. What NVIDIA’s financing bill means for the price you pay.
- Citadel bought the AI fire sale. The seller had run out of time.
Up 439% in the first half, down about 67% in July: how an AI hedge fund ended up selling a roughly $16 billion stock book to Citadel at a discount.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchMore tickers reported by Gilbert Cisneros
Gilbert Cisneros and ARQT: questions
Did Gilbert Cisneros buy or sell ARQT?
House Clerk filings for 2025 and 2026 show 2 purchases and 1 sale of Arcutis Biotherapeutics, Inc. - Common stock (ARQT) reported by Gilbert Cisneros, between 2025-12-11 and 2026-05-29. Reported owner: Self.
How much ARQT did Gilbert Cisneros trade?
Filings disclose brackets, not exact values. Summing the low and high ends of each bracket gives $3K – $45K across 3 transactions. Yield Theory does not estimate share counts, prices, or gains from these ranges.
When was the last ARQT filing by Gilbert Cisneros?
The most recent filing that includes a ARQT trade was filed on 2026-06-08. New filings appear in the House Clerk index and are picked up when the dataset is refreshed.
Yield Theory is not affiliated with any elected official or with Arcutis Biotherapeutics, Inc. - Common stock. Rows are parsed from public House Clerk periodic transaction reports; amounts are reported brackets and filings can be amended. This page is educational and is not investment advice.
Don’t copy the filing. Read the thesis.
Gilbert Cisneros ARQT disclosures are delayed, ranged, and often a spouse. Members get the monthly call that treats those rows as one input, then names catalysts, risks, and what would change the view. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included